Organization | Institut Jules Bordet

Institut Jules Bordet Report issue

Academic/Hospital Phase 1 Phase 3

Organization Overview

First Clinical Trial

2018

NCT03767335

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2018

Timeline

NOW

Now

Alternative names

Institute Jules Bordet - Boulevard De Waterloo 125 - B-1000 Brussels, Belgium | Institut Jules Bordet/Clinical Trials Support Unit (IJB/CTSU)

Active Ingredients

Drugs in Phase 3 Trials (4)

atezolizumab (Tecentriq) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

doxorubicin (Doxil) (1 trial)

paclitaxel (taxol) (1 trial)

Drugs in Phase 1 Trials (3)

fulvestrant (faslodex) (1 trial)

men1611 (1 trial)

trastuzumab (herceptin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Breast Neoplasms (Phase 3)

Triple Negative Breast Neoplasms (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 2
# of Trial APIs: 7